Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

NCT05153239 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

705

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Small Cell Lung Cancer

Interventions

DRUG: Irinotecan
DRUG: Lurbinectedin
DRUG: Irinotecan
DRUG: Topotecan
DRUG: Lurbinectedin

Sponsor

PharmaMar